Endo completes tender for Indevus

Endo Pharmaceuticals has successfully completed the tender offer of $370.0 million by its wholly-\owned subsidiary, BTB Purchaser, for all  of the outstanding shares of common stock of Indevus Pharmaceuticals  (Marketletter January 12). American Stock Transfer & Trust Co, the  depositary for the tender offer, has advised Endo that, as of 5:00 p.m.,  New York City time, on February 20, the initial expiration of the tender  offer, around 61,358,944 shares were validly tendered and not withdrawn,  representing around 78% of Indevus' issued and outstanding shares. All  validly-tendered shares have been accepted for payment and Endo says it  will pay for all of these promptly.